PFIZER INC
Q4 2024 Form 13-F

NEW YORK, DELAWARE
CIK 0000078003 · Publicly traded company
$2.6B Reported Value Total
Reported value
$2.6B
Quarter over quarter
0.0%
Holdings
23
Top-10 concentration
98.4%

Key People

Directors & officers from Form 4 filings
Bourla Albert
Chairman & CEO
Damico Jennifer B.
SVP & Controller
Baum Andrew
Executive Vice President
Boshoff Christoffel
President, R&D
De Germay Alexandre
Executive Vice President
Denton David M
Chief Financial Officer & EVP

Description and Activity

Pfizer is a global biopharmaceutical company that primarily provides medicines and vaccines addressing a range of diseases. Its main product categories include internal medicine, vaccines, inflammation and immunology, rare diseases, and oncology. Pfizer operates through three segments: Biopharma, which is the main segment, PC1 for contract development and manufacturing, and Pfizer Ignite, which offers R&D services to biotech firms.

Pfizer generates revenue through the sale of its biopharmaceutical products, with significant contributions from international markets such as China and Japan. The company's primary customers include wholesalers, hospitals, and government agencies, with vaccines often sold directly to the U.S. federal government and other international institutions. Pfizer's revenue is impacted by competition from generic and biosimilar manufacturers, pricing pressures from managed care organizations, and patent expirations.

Pfizer's operational structure includes divisions for oncology, U.S. commercial operations, and international commercial operations. Key factors impacting its business performance include competition, patent expirations, pricing and reimbursement challenges, and regulatory compliance. The company actively manages its R&D pipeline, focusing on enhancing existing products and discovering new indications through both internal efforts and external collaborations.

Company description summarized from 10-K filing.

Filing Navigation

13F Metrics

Loading 13F Metrics

Q4 2024 13F record

Q4 2024 13F filing summary

Q4 2024 Form 13F portfolio summary
Period of report December 31, 2024
Filed February 14, 2025
Form 13F-HR
Reported value $2.6B
Positions 23
Change in reported value First reported quarter
Top-10 concentration 98.4%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q2 2026 13F
Filed Aug 13, 2026
17 $170.4M
Q1 2026 13F
Filed May 12, 2026
18 $238.8M
Q4 2025 13F
Filed Feb 12, 2026
18 $236.5M
Q3 2025 13F
Filed Nov 13, 2025
21 $437.5M
Q2 2025 13F
Filed Aug 11, 2025
21 $576.2M
Q1 2025 13F
Filed May 13, 2025
21 $500.8M
Q4 2024 13F
Filed Feb 14, 2025
23 $2.6B

Top 20 holdings · Q4 2024

Largest Q4 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 HLN HALEON PLC $1.9B 72.59%
2 BNTX BIONTECH SE $416.9M 16.08%
3 ARVN ARVINAS INC $66.3M 2.56%
4 ALLO ALLOGENE THERAPEUTICS INC $46.9M 1.81%
5 ORIC ORIC PHARMACEUTICALS INC $43.4M 1.67%
6 TRML TOURMALINE BIO INC $25.8M 1.0%
7 WVE WAVE LIFE SCIENCES LTD $23.2M 0.89%
8 BHVN BIOHAVEN LTD $18.9M 0.73%
9 AKRO AKERO THERAPEUTICS INC $15.7M 0.6%
10 PYXS PYXIS ONCOLOGY INC $11.0M 0.42%
11 CRDF CARDIFF ONCOLOGY INC $10.5M 0.4%
12 CRBU CARIBOU BIOSCIENCES INC $7.5M 0.29%
13 ZURA ZURA BIO LTD $7.4M 0.29%
14 CELC CELCUITY INC $4.6M 0.18%
15 EPIX ESSA PHARMA INC $3.0M 0.12%
16 ZNTL ZENTALIS PHARMACEUTICALS INC $2.9M 0.11%
17 SPRO SPERO THERAPEUTICS INC $2.4M 0.09%
18 NXTC NEXTCURE INC $1.9M 0.07%
19 ANTX AN2 THERAPEUTICS INC $987.1K 0.04%
20 QTTB Q32 BIO INC $955.6K 0.04%

Values as reported on the Q4 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings